QT Imaging

Executive Summary

QT Imaging is a privately held medical device company headquartered in Novato, California, focused on transforming breast cancer screening and monitoring through non-invasive, radiation-free ultrasound imaging. Founded in 2012, the company has developed the QTI Breast Acoustic CT™ scanner, which combines Quantitative Transmission ultrasound technology with artificial intelligence and biomarkers to produce high-resolution 3D breast images without the need for ionizing radiation or breast compression. This approach aims to address the limitations of traditional mammography, including patient discomfort and false positives, while offering a safer alternative for routine screening and monitoring of high-risk populations. Although QT Imaging has not yet disclosed its total funding or valuation, its technology has the potential to disrupt the $10+ billion breast cancer diagnostics market by providing a cost-effective, safer, and more accessible imaging modality. However, the company faces significant hurdles, including regulatory approval from the FDA, clinical validation against established screening methods, and commercialization scaling to compete with incumbent mammography and tomosynthesis systems. Its success hinges on securing regulatory clearances, building clinical evidence, and forming strategic partnerships with healthcare providers and distributors.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for QTI Breast Acoustic CT Scanner70% success
• Q3 2026Pivotal Clinical Trial Results Published or Presented60% success
• Q2 2026Strategic Funding Round or Corporate Partnership50% success